Published in Nucleic Acids Res on February 01, 2005
Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe (2008) 3.14
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Genetic therapies against HIV. Nat Biotechnol (2007) 2.50
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
A genome-wide short hairpin RNA screening of jurkat T-cells for human proteins contributing to productive HIV-1 replication. J Biol Chem (2009) 2.40
The evolution of RNAi as a defence against viruses and transposable elements. Philos Trans R Soc Lond B Biol Sci (2009) 2.35
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol Biol (2007) 2.20
RNAi targeting of West Nile virus in mosquito midguts promotes virus diversification. PLoS Pathog (2009) 2.13
Effect of target secondary structure on RNAi efficiency. RNA (2007) 1.76
Viruses and microRNAs: RISCy interactions with serious consequences. Genes Dev (2011) 1.66
Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev (2009) 1.65
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta (2008) 1.64
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Rich RNA Structure Landscapes Revealed by Mutate-and-Map Analysis. PLoS Comput Biol (2015) 1.44
Antiviral silencing in animals. FEBS Lett (2005) 1.36
Interplay between HIV-1 infection and host microRNAs. Nucleic Acids Res (2011) 1.36
Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther (2008) 1.32
RNA viruses and the host microRNA machinery. Nat Rev Microbiol (2013) 1.31
HIV-1 Tat protein promotes neuronal dysfunction through disruption of microRNAs. J Biol Chem (2011) 1.28
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
MicroRNAs and the regulation of vector tropism. Mol Ther (2008) 1.25
MicroRNAs and human retroviruses. Biochim Biophys Acta (2011) 1.23
Mobilization-competent Lentiviral Vector-mediated Sustained Transcriptional Modulation of HIV-1 Expression. Mol Ther (2008) 1.23
RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22
Effective suppression of human immunodeficiency virus type 1 through a combination of short- or long-hairpin RNAs targeting essential sequences for retroviral integration. J Virol (2006) 1.21
MicroRNA-guided processing impairs Plum pox virus replication, but the virus readily evolves to escape this silencing mechanism. J Virol (2006) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
HIV-1 Tat interaction with Dicer: requirement for RNA. Retrovirology (2006) 1.20
Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J Virol (2005) 1.19
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res (2010) 1.17
Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs. J Virol (2006) 1.12
Small non-coding RNAs, mammalian cells, and viruses: regulatory interactions? Retrovirology (2007) 1.12
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11
Advances in RNA structure prediction from sequence: new tools for generating hypotheses about viral RNA structure-function relationships. J Virol (2009) 1.09
Optimal design and validation of antiviral siRNA for targeting HIV-1. Retrovirology (2007) 1.09
HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host Microbe (2008) 1.07
Human Immunodeficiency Virus-Type 1 LTR DNA contains an intrinsic gene producing antisense RNA and protein products. Retrovirology (2006) 1.07
Novel Pol II fusion promoter directs human immunodeficiency virus type 1-inducible coexpression of a short hairpin RNA and protein. J Virol (2006) 1.07
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
Molecular evolution of a viral non-coding sequence under the selective pressure of amiRNA-mediated silencing. PLoS Pathog (2009) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
MicroRNA antagonism of the picornaviral life cycle: alternative mechanisms of interference. PLoS Pathog (2010) 1.04
RNAsnp: efficient detection of local RNA secondary structure changes induced by SNPs. Hum Mutat (2013) 1.03
Anti-viral RNA silencing: do we look like plants? Retrovirology (2006) 1.03
Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. PLoS One (2009) 1.02
Large-scale production of dsRNA and siRNA pools for RNA interference utilizing bacteriophage phi6 RNA-dependent RNA polymerase. RNA (2007) 1.01
HIV develops indirect cross-resistance to combinatorial RNAi targeting two distinct and spatially distant sites. Mol Ther (2012) 1.01
Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS One (2012) 1.01
Impact of target mRNA structure on siRNA silencing efficiency: A large-scale study. Biotechnol Bioeng (2008) 0.98
96 shRNAs designed for maximal coverage of HIV-1 variants. Retrovirology (2009) 0.98
Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther (2012) 0.98
Appearances can be deceptive: revealing a hidden viral infection with deep sequencing in a plant quarantine context. PLoS One (2014) 0.98
Hairpin-induced tRNA-mediated (HITME) recombination in HIV-1. Nucleic Acids Res (2006) 0.97
Application of RNA silencing to plant disease resistance. Silence (2012) 0.96
The efficacy of generating three independent anti-HIV-1 siRNAs from a single U6 RNA Pol III-expressed long hairpin RNA. PLoS One (2008) 0.96
Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome. Retrovirology (2007) 0.95
Novel HIV-1 therapeutics through targeting altered host cell pathways. Expert Opin Biol Ther (2009) 0.94
Antiviral RNAi: translating science towards therapeutic success. Pharm Res (2011) 0.94
Destabilization of the TAR hairpin affects the structure and function of the HIV-1 leader RNA. Nucleic Acids Res (2008) 0.94
Silencing of hepatitis A virus infection by small interfering RNAs. J Virol (2006) 0.93
MicroRNAs - Biology and clinical applications. J Oral Maxillofac Pathol (2014) 0.93
Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies. RNA (2010) 0.92
A re-examination of global suppression of RNA interference by HIV-1. PLoS One (2011) 0.92
A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics (2009) 0.91
HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One (2011) 0.91
HIV-1 evolution: frustrating therapies, but disclosing molecular mechanisms. Philos Trans R Soc Lond B Biol Sci (2010) 0.90
Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity. RNA (2014) 0.89
Tempo and mode of plant RNA virus escape from RNA interference-mediated resistance. J Virol (2011) 0.88
Stable gene transfer of CCR5 and CXCR4 siRNAs by sleeping beauty transposon system to confer HIV-1 resistance. AIDS Res Ther (2008) 0.88
Silencing viral microRNA as a novel antiviral therapy? J Biomed Biotechnol (2009) 0.88
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. Mol Ther Nucleic Acids (2013) 0.87
Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Res Ther (2011) 0.87
Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites. Retrovirology (2007) 0.87
HIV-l and the microRNA-guided silencing pathway: an intricate and multifaceted encounter. Virus Res (2006) 0.87
Interfering RNA and HIV: reciprocal interferences. PLoS Pathog (2008) 0.87
RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther (2010) 0.87
RNAi-mediated inhibition of HIV-1 by targeting partially complementary viral sequences. Nucleic Acids Res (2009) 0.86
In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology (2010) 0.86
Emergence of a complex relationship between HIV-1 and the microRNA pathway. Methods Mol Biol (2009) 0.86
Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. Virol J (2009) 0.86
RNA interference against animal viruses: how morbilliviruses generate extended diversity to escape small interfering RNA control. J Virol (2011) 0.85
HIV-1 Escape From RNAi Antivirals: Yet Another Houdini Action? Mol Ther Nucleic Acids (2012) 0.84
RNA silencing and HIV: a hypothesis for the etiology of the severe combined immunodeficiency induced by the virus. Retrovirology (2008) 0.83
Identification of short hairpin RNA targeting foot-and-mouth disease virus with transgenic bovine fetal epithelium cells. PLoS One (2012) 0.83
Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. Virol J (2012) 0.83
Current progress and challenges in HIV gene therapy. Future Virol (2011) 0.82
On the role of four small hairpins in the HIV-1 RNA genome. RNA Biol (2013) 0.82
In vivo therapeutic potential of Dicer-hunting siRNAs targeting infectious hepatitis C virus. Sci Rep (2014) 0.82
Full-length RNA structure prediction of the HIV-1 genome reveals a conserved core domain. Nucleic Acids Res (2015) 0.82
Selection of RNAi-based inhibitors for anti-HIV gene therapy. World J Virol (2012) 0.81
Mechanistic insights on the Dicer-independent AGO2-mediated processing of AgoshRNAs. RNA Biol (2015) 0.81
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Selection of potent non-toxic inhibitory sequences from a randomized HIV-1 specific lentiviral short hairpin RNA library. PLoS One (2010) 0.81
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol (1999) 41.48
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell (2000) 20.32
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 14.37
ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 10.20
Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science (1995) 10.02
Mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. Cell (1999) 9.01
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol (2002) 8.31
Sequence requirements for micro RNA processing and function in human cells. RNA (2003) 7.46
Kinetic analysis of the RNAi enzyme complex. Nat Struct Mol Biol (2004) 7.26
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09
Effective expression of small interfering RNA in human cells. Nat Biotechnol (2002) 6.02
Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res (2002) 5.93
Modulation of HIV-1 replication by RNA interference. Nature (2002) 5.90
Gene silencing as an adaptive defence against viruses. Nature (2001) 5.73
Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI. Virology (1991) 5.54
RNA silencing in plants--defense and counterdefense. Science (2001) 5.01
Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res (2003) 3.85
Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol (2002) 3.42
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem (2002) 3.32
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
Human immunodeficiency virus type 1 escape from RNA interference. J Virol (2003) 3.01
Natural HIV-1 NEF accelerates virus replication in primary human lymphocytes. Virology (1992) 2.76
The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res (2003) 2.64
A general and fast method to generate multiple site directed mutations. Nucleic Acids Res (1992) 2.51
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J Biol Chem (2003) 2.29
HIV-1 encoded candidate micro-RNAs and their cellular targets. Retrovirology (2004) 2.23
HIV-1 nef suppression by virally encoded microRNA. Retrovirology (2004) 2.05
The gene-silencing efficiency of siRNA is strongly dependent on the local structure of mRNA at the targeted region. Biochem Biophys Res Commun (2004) 1.77
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
RNA interference--a new weapon against HIV and beyond. N Engl J Med (2002) 1.68
Comparison of 5' and 3' long terminal repeat promoter function in human immunodeficiency virus. J Virol (1994) 1.41
Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Res (2003) 1.35
Effects on RNAi of the tight structure, sequence and position of the targeted region. Nucleic Acids Res (2004) 1.26
RNA interference as an antiviral approach: targeting HIV-1. Curr Opin Mol Ther (2004) 1.07
RNA interference: a promising approach to antiviral therapy? Trends Mol Med (2002) 1.02
Identification of a new human coronavirus. Nat Med (2004) 11.24
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS (2004) 2.51
Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther (2006) 2.48
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC Infect Dis (2005) 2.28
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther (2008) 2.14
RNA interference against viruses: strike and counterstrike. Nat Biotechnol (2007) 2.14
Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem (2004) 2.06
In HIV-1 pathogenesis the die is cast during primary infection. AIDS (2007) 2.04
Croup is associated with the novel coronavirus NL63. PLoS Med (2005) 2.03
Detection of new viruses by VIDISCA. Virus discovery based on cDNA-amplified fragment length polymorphism. Methods Mol Biol (2008) 1.95
Retroviral superinfection resistance. Retrovirology (2005) 1.82
A novel long distance base-pairing interaction in human immunodeficiency virus type 1 RNA occludes the Gag start codon. J Biol Chem (2002) 1.81
Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol (2002) 1.78
The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol (2003) 1.71
Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J Virol (2008) 1.71
Inhibition of virus replication by RNA interference. J Biomed Sci (2003) 1.70
Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res (2008) 1.65
Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology (2006) 1.64
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64
Highly sensitive methods based on seminested real-time reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 unspliced and multiply spliced RNA and proviral DNA. J Clin Microbiol (2008) 1.61
The novel human coronaviruses NL63 and HKU1. J Virol (2006) 1.59
Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol (2004) 1.53
Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol (2007) 1.52
Multiple secondary structure rearrangements during HIV-1 RNA dimerization. Biochemistry (2002) 1.50
Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol (2007) 1.50
Microprocessor, Setx, Xrn2, and Rrp6 co-operate to induce premature termination of transcription by RNAPII. Cell (2012) 1.49
In vitro evidence that the untranslated leader of the HIV-1 genome is an RNA checkpoint that regulates multiple functions through conformational changes. J Biol Chem (2002) 1.48
The tRNA primer activation signal in the human immunodeficiency virus type 1 genome is important for initiation and processive elongation of reverse transcription. J Virol (2002) 1.40
Mosaic structure of human coronavirus NL63, one thousand years of evolution. J Mol Biol (2006) 1.40
Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1. J Virol (2008) 1.40
Genome structure and transcriptional regulation of human coronavirus NL63. Virol J (2004) 1.39
Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology (2013) 1.37
Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev (2006) 1.37
Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology (2010) 1.36
The HIV-1 leader RNA conformational switch regulates RNA dimerization but does not regulate mRNA translation. Biochemistry (2005) 1.36
Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol (2004) 1.34
Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J Clin Invest (2005) 1.34
Lack of detection of XMRV in seminal plasma from HIV-1 infected men in The Netherlands. PLoS One (2010) 1.34
Recent developments in pain in dementia. BMJ (2005) 1.33
Deep sequencing of virus-infected cells reveals HIV-encoded small RNAs. Nucleic Acids Res (2011) 1.32
A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol (2010) 1.30
A riboswitch regulates RNA dimerization and packaging in human immunodeficiency virus type 1 virions. J Virol (2004) 1.30
Human parechovirus type 1, 3, 4, 5, and 6 detection in picornavirus cultures. J Clin Microbiol (2007) 1.28
A systematic analysis of the effect of target RNA structure on RNA interference. Nucleic Acids Res (2007) 1.27
The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. J Virol (2011) 1.26
Dimerization and template switching in the 5' untranslated region between various subtypes of human immunodeficiency virus type 1. J Virol (2003) 1.26
Comparison of single regulated lentiviral vectors with rtTA expression driven by an autoregulatory loop or a constitutive promoter. Nucleic Acids Res (2005) 1.23
Differential susceptibility of naïve, central memory and effector memory T cells to dendritic cell-mediated HIV-1 transmission. Retrovirology (2006) 1.23
The TAR hairpin of human immunodeficiency virus type 1 can be deleted when not required for Tat-mediated activation of transcription. J Virol (2007) 1.22
RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol (2007) 1.22
Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21
Sialoadhesin (CD169) expression in CD14+ cells is upregulated early after HIV-1 infection and increases during disease progression. PLoS One (2007) 1.21
The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology (2006) 1.20
Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res (2002) 1.20
Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr (2008) 1.20
Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands. PLoS One (2009) 1.20
Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol (2006) 1.19
Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. J Virol (2005) 1.19
RNAi suppressors encoded by pathogenic human viruses. Int J Biochem Cell Biol (2008) 1.18
Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol Ther (2009) 1.18
Effects of random mutations in the human immunodeficiency virus type 1 transcriptional promoter on viral fitness in different host cell environments. J Virol (2006) 1.16
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
Modest nonadherence to antiretroviral therapy promotes residual HIV-1 replication in the absence of virological rebound in plasma. J Infect Dis (2012) 1.13
The NS3 protein of rice hoja blanca virus complements the RNAi suppressor function of HIV-1 Tat. EMBO Rep (2009) 1.13
Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des (2010) 1.13
Probing alternative foldings of the HIV-1 leader RNA by antisense oligonucleotide scanning arrays. Nucleic Acids Res (2004) 1.12
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem (2009) 1.11
SHAPE-directed discovery of potent shRNA inhibitors of HIV-1. Mol Ther (2012) 1.11
The biased nucleotide composition of the HIV genome: a constant factor in a highly variable virus. Retrovirology (2012) 1.10
Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol (2008) 1.10
The carbohydrate at asparagine 386 on HIV-1 gp120 is not essential for protein folding and function but is involved in immune evasion. Retrovirology (2008) 1.10
Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol (2011) 1.09
Triple HIV-1 infection. N Engl J Med (2005) 1.09
Antibacterial and antiviral effects of milk proteins and derivatives thereof. Curr Pharm Des (2003) 1.08
RNAi and cellular miRNAs in infections by mammalian viruses. Methods Mol Biol (2011) 1.08
Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology (2007) 1.08
Inhibition of human immunodeficiency virus type 1 replication with artificial transcription factors targeting the highly conserved primer-binding site. J Virol (2006) 1.07
Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother (2006) 1.07
A doubly fluorescent HIV-1 reporter shows that the majority of integrated HIV-1 is latent shortly after infection. J Virol (2013) 1.07
Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res (2007) 1.06
Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses (2004) 1.06
Dicer-independent processing of short hairpin RNAs. Nucleic Acids Res (2013) 1.06
The HIV RNA setpoint theory revisited. Retrovirology (2007) 1.06
A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. J RNAi Gene Silencing (2005) 1.06
Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors. Antiviral Res (2010) 1.05
Anticipating and blocking HIV-1 escape by second generation antiviral shRNAs. Retrovirology (2010) 1.05
The effect of depression on social engagement in newly admitted Dutch nursing home residents. Gerontologist (2003) 1.05